An observational study in Platelet Levels and Mean Platelet Volume in Patients With CF, sponsored by Mersin Training and Research Hospital. Completed at 1 site in Turkey. Open to participants aged 12 Months to 18 Years. Per ClinicalTrials.gov, last updated 2022-05-20.
Sponsored by Mersin Training and Research Hospital · Observational
Cystic fibrosis (CF) is a chronic multiorgan disorder caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene. Chronic airway infection by bacterial pathogens accounts for the progressive, suppurative pulmonary disease that leads to significant morbidity and mortality in patients with CF. Neutrophil recruitment to the lungs accounts the most important contributor to pulmonary destruction. However, there is evidence that platelets may also have an important role in the pathogenesis of inflammation. To our knowledge, there is few information in platelet levels in patients with cystic fibrosis during pulmonary exacerbation, chronic airway colonization and when stable.
Airway inflammation in CF is predominantly neutrophilic in nature with increased concentrations of pro-inflammatory mediators include TNF-α, IL-1β, IL-6, IL-8, IL-17, IL-33, GM-CSF and G-CSF. In addition, other cell types including macrophages and T-lymphocytes are expressed by CFTR and contribute to the CF inflammatory response.
Researches have indicated that platelets may also have a significant contribution to the inflammation. Platelet depletion or antiplatelet therapies attenuate injury and mortality in animal models of acute lung injury. More importantly, CFTR expression has been shown on human platelets. Recent data suggests that CF patients have an increase in circulating activated platelets and platelet reactivity.
Taken together, these observations support a potentially important role of platelets in regulating lung inflammation in CF. However, there are few studies examine platelet and lung inflammation interraction in patients with CF. Therefore we aimed to investigate platelet count (PC) and mean platelet volume (MPV) levels in various conditions in our CF patients.
2,044 studies on the registry are indexed under Pneumonia; 283 are open to participants now.
This study's enrollment of 53 is below the median of 203 across 688 observational studies indexed under Pneumonia.
Browse Pneumonia studies →Mersin Training and Research Hospital is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Cystic fibrosis patients
Exclusion Criteria:
Platelet count (PC) and mean platelet volume (MPV) during pulmonary exacerbation.
Other: platelet count and mean platelet volume are obtained from whole blood count
PC and MPV during no pulmonary exacerbation
Other: platelet count and mean platelet volume are obtained from whole blood count
PC and MPV during chronic colonization in acute pulmonary exacerbation
Other: platelet count and mean platelet volume are obtained from whole blood count
PC and MPV during chronic colonization without pulmonary exacerbation
Other: platelet count and mean platelet volume are obtained from whole blood count
PC and MPV during chronic colonization without pulmonary exacerbation
Other: platelet count and mean platelet volume are obtained from whole blood count
PC and MPV during no chronic colonization without pulmonary exacerbation
Other: platelet count and mean platelet volume are obtained from whole blood count
The records of cystic fibrosis patients will be retrospectively evaluated for acute pulmonary exacerbation, chronic airway colonization for bacteria, clinical stable status. PC and MPV will be obtained and matched in 6 groups (described above). Then, PC and MPV will be compared among the groups.
Platelet levels and mean platelet volume in acute pulmonary infection in patients with cystic fibrosis
Elevated platelet level count (x103/uL) and increased mean platelet volume (fl) during acute pulmonary exacerbation in cystic fibrosis patients
Time frame: 2 weeks
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mersin Training and Research Hospital